Form 4 holding
Chief Legal Officer
Vera Therapeutics, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 42,403
- Estimated value
- $2,147,287
- Report date
- 23 Mar 2026
- Price
- $50.64
- Ownership
- Direct
Jane Wright-Mitchell
Insider Reports History
- Reporting-owner location
- Brisbane, CA
- Latest reporting-owner signature
- /s/ Joseph R. Young, Attorney-in-Fact
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Jane Wright-Mitchell
Form 4 holding
General Counsel
Vaxcyte, Inc.
- Security class
- Common Stock
- Shares / value
- 3,125
- Estimated value
- $202,438
- Report date
- 16 Aug 2021
- Price
- $64.78
- Ownership
- Direct
Form 4 holding
General Counsel
Vaxcyte, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 187,468
- Estimated value
- Report date
- 16 Aug 2021
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Legal Officer
Vera Therapeutics, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 56,850
- Estimated value
- Report date
- 23 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
Insider Reports Filed by Jane Wright-Mitchell
4
VERA
Vera Therapeutics, Inc.
- Report period
- 23 Mar 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 25 Mar 2026, 19:08
- Role
- Chief Legal Officer
- Next action
- Open filing details
3
VERA
Vera Therapeutics, Inc.
- Report period
- 23 Mar 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 25 Mar 2026, 19:06
- Role
- Chief Legal Officer
- Next action
- Open filing details
4
PCVX
Vaxcyte, Inc.
- Report period
- 16 Aug 2021
- Transactions
- 3
- Transaction value
- -$59,925
- Accepted by SEC
- 18 Aug 2021, 18:02
- Role
- General Counsel
- Next action
- Open filing details
4
PCVX
Vaxcyte, Inc.
- Report period
- 12 Aug 2021
- Transactions
- 3
- Transaction value
- -$239,700
- Accepted by SEC
- 16 Aug 2021, 16:31
- Role
- General Counsel
- Next action
- Open filing details